IOVA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IOVA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Iovance Biotherapeutics's Operating Income for the three months ended in Mar. 2024 was $-117.72 Mil. Iovance Biotherapeutics's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Iovance Biotherapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Iovance Biotherapeutics's Interest Coverage or its related term are showing as below:
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Iovance Biotherapeutics's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Iovance Biotherapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Interest Coverage | Get a 7-Day Free Trial | N/A | N/A | N/A | N/A | N/A |
Iovance Biotherapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Interest Coverage | Get a 7-Day Free Trial | N/A | N/A | N/A | N/A | N/A |
For the Biotechnology subindustry, Iovance Biotherapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Iovance Biotherapeutics's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
If Interest Expense is negative and Operating Income is positive, then
Interest Coverage | = | -1 | * | Operating Income | / | Interest Expense |
Else if Interest Expense is negative and Operating Income is negative, then
The company did not have earnings to cover the interest expense. |
Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then
The company had no debt (1). |
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Iovance Biotherapeutics's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as
Here, for the fiscal year that ended in Dec. 2023, Iovance Biotherapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-460.56 Mil. And its Long-Term Debt & Capital Lease Obligation was $68.09 Mil.
GuruFocus does not calculate Iovance Biotherapeutics's interest coverage with the available data. |
Iovance Biotherapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
Here, for the three months ended in Mar. 2024, Iovance Biotherapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-117.72 Mil. And its Long-Term Debt & Capital Lease Obligation was $73.29 Mil.
GuruFocus does not calculate Iovance Biotherapeutics's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's Financial Strength is.
Iovance Biotherapeutics (NAS:IOVA) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Thank you for viewing the detailed overview of Iovance Biotherapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.
Merrill A Mcpeak | director | PO BOX 500 (M/S 55-985), 14200 SW KARL BRAUN DRIVE, BEAVERTON OR 97077-0001 |
Wayne P. Rothbaum | director | C/O QUOGUE CAPITAL LLC, 1285 AVENUE OF THE AMERICAS, 35TH FLOOR, NEW YORK NY 10019 |
Wendy L Yarno | director | |
Frederick G Vogt | officer: General Counsel | 2120 HEMLOCK RD., WEST NORRITON PA 19403 |
Iain D. Dukes | director | 112 W. 34TH STREET, 17TH FLOOR, NEW YORK NY 10120 |
Wendy L Dixon | director | |
Ryan D Maynard | director | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080 |
Michael Weiser | director | C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133 |
Igor Bilinsky | officer: Chief Operating Officer | C/O VICAL INCORPORATED, 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121 |
Jean-marc Bellemin | officer: Chief Financial Officer | C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
Michael Swartzburg | officer: VP, Finance | C/O AVALANCHE BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025 |
Athena Countouriotis | director | C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121 |
Finckenstein Friedrich Graf | officer: Chief Medical Officer | 999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070 |
Timothy E Morris | officer: Chief Financial Officer | ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063 |
Maria Fardis | director, officer: President and CEO | C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
From GuruFocus
By Marketwired • 09-27-2023
By GlobeNewswire • 11-17-2023
By Marketwired • 07-10-2023
By Marketwired • 09-07-2023
By PRNewswire • 01-23-2024
By PRNewswire • 01-14-2024
By Marketwired • 09-22-2023
By Marketwired • 07-10-2023
By Marketwired • 07-25-2023
By Marketwired • 08-18-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.